Mentholatum Issues Nationwide Recall of Rohto Eye Drops - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mentholatum Issues Nationwide Recall of Rohto Eye Drops



Mentholatum, a manufacturer of pharmaceuticals, and other healthcare products, is conducting a voluntary recall to the retail level of eye drops made in Vietnam due to a manufacturing review at the production facility in Vietnam involving sterility controls.

The recall includes only lots of Rohto Arctic, Rohto Ice, Rohto Hydra, Rohto Relief, and Rohto Cool eye drops that were manufactured in Vietnam and does not include eye drops made in Japan. Products manufactured in Japan are not included in this recall and continue to be available to consumers.

To date, there has been no evidence indicating that product does not meet specifications; however, the company is taking this action as a precautionary measure.

Source: Mentholatum

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here